Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shreyaskumar Patel

Showing results (71-80 of 116) with videos related to

Pageof 12
Sort By:
The Oncologist|December 8, 2017
Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell TumorBrian A Menegaz, Branko Cuglievan, Jalen Benson, et al.
American Journal of Clinical Oncology|August 23, 2019
Extraskeletal Myxoid Chondrosarcomas: Combined Modality Therapy With Both Radiation and Surgery Improves Local ControlAndrew J Bishop, Justin E Bird, Anthony P Conley, et al.
Cancer|November 17, 2005
Angiosarcoma of the breastStephan A Vorburger, Yan Xing, Kelly K Hunt, et al.
Cancer|July 17, 2015
Phase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcomaWilliam W Tseng, Shouhao Zhou, Christina A To, et al.
Oncotargets and Therapy|May 17, 2021
A Phase I Trial of the MET/<i>ALK/ROS1</i> Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid MalignanciesSarina A Piha-Paul, Ecaterina E Dumbrava, Binoj C Nair, et al.
Spine|August 25, 2017
Ewing Sarcoma of the Spine: Prognostic Variables for Survival and Local Control in Surgically Treated PatientsRaphaële Charest-Morin, Michael S Dirks, Shreyaskumar Patel, et al.
Cancer|May 17, 2002
Tumor volume as a prognostic factor for sarcomatosisMalcolm M Bilimoria, Daniel J Holtz, Nadeem Q Mirza, et al.
Scientific Reports|August 27, 2017
Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patientsGustavo Schvartsman, Michael J Wagner, Behrang Amini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2014
Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trialChristopher L Corless, Karla V Ballman, Cristina R Antonescu, et al.
Cancers|May 18, 2019
MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/MyxofibrosarcomaAnthony P Conley, Wei-Lien Wang, John A Livingston, et al.
Pageof 12

Showing results (71-80 of 116) with videos related to

Sort By:
Pageof 12
The Oncologist|December 8, 2017
Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell TumorBrian A Menegaz, Branko Cuglievan, Jalen Benson, et al.
American Journal of Clinical Oncology|August 23, 2019
Extraskeletal Myxoid Chondrosarcomas: Combined Modality Therapy With Both Radiation and Surgery Improves Local ControlAndrew J Bishop, Justin E Bird, Anthony P Conley, et al.
Cancer|November 17, 2005
Angiosarcoma of the breastStephan A Vorburger, Yan Xing, Kelly K Hunt, et al.
Cancer|July 17, 2015
Phase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcomaWilliam W Tseng, Shouhao Zhou, Christina A To, et al.
Oncotargets and Therapy|May 17, 2021
A Phase I Trial of the MET/<i>ALK/ROS1</i> Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid MalignanciesSarina A Piha-Paul, Ecaterina E Dumbrava, Binoj C Nair, et al.
Spine|August 25, 2017
Ewing Sarcoma of the Spine: Prognostic Variables for Survival and Local Control in Surgically Treated PatientsRaphaële Charest-Morin, Michael S Dirks, Shreyaskumar Patel, et al.
Cancer|May 17, 2002
Tumor volume as a prognostic factor for sarcomatosisMalcolm M Bilimoria, Daniel J Holtz, Nadeem Q Mirza, et al.
Scientific Reports|August 27, 2017
Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patientsGustavo Schvartsman, Michael J Wagner, Behrang Amini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2014
Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trialChristopher L Corless, Karla V Ballman, Cristina R Antonescu, et al.
Cancers|May 18, 2019
MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/MyxofibrosarcomaAnthony P Conley, Wei-Lien Wang, John A Livingston, et al.
Pageof 12